The difference between Ozempic and Wegovy — and why it matters for weight loss

Same molecule, different jobs, how the licensing split happened

Semaglutide was first developed as a diabetes treatment, and Ozempic was its original commercial form. Clinical trials then tested much higher doses for weight management, and the results were striking enough that regulators authorised a separate product (Wegovy) specifically for that purpose. If you have been wondering whether there is any difference between Ozempic and Wegovy, the short answer is that the NHS semaglutide medicines page treats them as distinct entries because they are, legally speaking, different medicines despite sharing an active ingredient.

The practical upshot is straightforward. A GP prescribing Ozempic to a patient with type 2 diabetes is working fully within that medicine's licence. A clinician prescribing it to someone who only wants to lose weight is prescribing off-label, which is sometimes appropriate but requires a clear clinical rationale and informed consent, it is not simply a cheaper workaround for getting the Wegovy dose.

Wegovy's dose ceiling matters here. The diabetes doses of semaglutide top out at 1mg (and 2mg in some formulations), whereas Wegovy's maintenance dose is 2.4mg weekly, the dose at which the weight-loss trial data was generated. There is also now a 7.2mg Wegovy pen, approved by the MHRA in April 2026, for adults with a BMI of 30 or above. That dose simply does not exist in the Ozempic range. If the clinical effect you are after requires those higher doses, Ozempic cannot get you there within its licence.

What the trial data actually compares

The weight-loss evidence for Wegovy comes primarily from the STEP programme. In the STEP 1 trial, adults without diabetes achieved around 15% average body-weight reduction over 68 weeks at the 2.4mg maintenance dose, alongside lifestyle changes, findings published in the New England Journal of Medicine. That trial enrolled people specifically for weight management, not diabetes control, which is why the data is considered the proper evidence base for Wegovy.

Ozempic's trials were designed around glycaemic outcomes in people with type 2 diabetes. Weight loss was observed as a secondary finding, but those participants had a different health profile, and the doses studied were lower. Citing Ozempic trial data to justify a weight-loss prescription is therefore mixing evidence bases in a way that regulators and prescribers tend to flag.

The practical difference for anyone exploring a direct Wegovy vs Ozempic comparison is that Wegovy has a purpose-built clinical dossier for weight management, and Ozempic does not. That is why NICE assessed them separately: Wegovy received its own appraisal under NICE TA875, setting out the conditions under which it can be recommended for weight management through the NHS. No equivalent NICE weight-loss appraisal exists for Ozempic.

What is actually licensed for weight loss in the UK right now

If weight management is the goal, there are two licensed injectable options in the UK: Wegovy (semaglutide) and Mounjaro (tirzepatide). Mounjaro works differently, it activates both the GLP-1 and GIP receptors, making it the only dual-agonist weight-loss medicine currently licensed here. Head-to-head trial data from SURMOUNT-5 showed greater average weight reduction with tirzepatide than with semaglutide 2.4mg over 72 weeks, though individual results vary and the right choice depends on your medical history.

Wegovy also now exists as a daily tablet. The MHRA approved oral semaglutide for weight management on 11 June 2026, making it the first oral GLP-1 licensed for this purpose in the UK. If injections are a barrier, that changes the picture considerably. You can read more about the full Wegovy treatment overview or explore weight-loss treatment options more broadly to see how these medicines sit alongside each other.

Saxenda (liraglutide) is a third licensed option (a once-daily GLP-1 injection) though if you're comparing injectable GLP-1 medicines, a separate look at the difference between Saxenda and Wegovy is worth your time. The key point is that Ozempic does not appear on this list, because it is not licensed for weight management in the UK, regardless of how widely it is discussed online.

Why this matters if you're thinking about an online prescription

A lot of people arrive at this question feeling genuinely confused, the two names appear almost interchangeably in the media, prices for Ozempic surface in the same searches as Wegovy, and the distinction between a licensed and an off-label use is not always explained. That confusion is understandable. Reading what people who have actually used Wegovy say about their experience can help ground the decision in something more concrete than marketing claims. What that confusion should not translate into, though, is accepting a prescription for Ozempic from a service that frames it as the equivalent of Wegovy for weight loss.

Any legitimate prescriber will know the difference and prescribe accordingly. Verifying the pharmacy is a sensible first step: the GPhC register lets you confirm that any online pharmacy is properly registered before you hand over personal or medical information. Red flags include services that offer these medicines without a clinical assessment, prices that sit far below the typical private market, or sellers that do not ask about your medical history at all.

At nume, our prescribers assess each consultation individually, your answers are read by a GPhC-registered Independent Prescriber, not processed by software. We dispense Wegovy and Mounjaro for weight management; we do not dispense Ozempic for weight loss, because it is not the licensed product for that purpose. If you would like to understand what the differences between Ozempic and Wegovy mean for your own treatment options, or if you'd like to explore whether Wegovy or Mounjaro might be suitable for you, you can speak to our prescribers through a free consultation, there's no obligation and no subscription.